tiprankstipranks
SAB Biotherapeutics Advances in Type 1 Diabetes Immunotherapy Trial
PremiumCompany AnnouncementsSAB Biotherapeutics Advances in Type 1 Diabetes Immunotherapy Trial
6M ago
SAB Biotherapeutics provides SAB-142 clinical trial progress update
Premium
The Fly
SAB Biotherapeutics provides SAB-142 clinical trial progress update
6M ago
SAB Biotherapeutics initiated with an Outperform at Oppenheimer
Premium
The Fly
SAB Biotherapeutics initiated with an Outperform at Oppenheimer
6M ago
SAB Biotherapeutics announces new name, SAB BIO for rebrand focus on type 1
PremiumThe FlySAB Biotherapeutics announces new name, SAB BIO for rebrand focus on type 1
8M ago
SAB Biotherapeutics initiated with Buy on risk/reward at Brookline
Premium
The Fly
SAB Biotherapeutics initiated with Buy on risk/reward at Brookline
9M ago
SAB Biotherapeutics initiated with a Buy at Brookline
Premium
The Fly
SAB Biotherapeutics initiated with a Buy at Brookline
9M ago
SAB Biotherapeutics provides SAB-142 trial update
PremiumThe FlySAB Biotherapeutics provides SAB-142 trial update
10M ago
SAB Biotherapeutics Advances SAB-142 in Phase One Trials
Premium
Company Announcements
SAB Biotherapeutics Advances SAB-142 in Phase One Trials
10M ago
SAB Biotherapeutics price target lowered to $6 from $10 at H.C. Wainwright
Premium
The Fly
SAB Biotherapeutics price target lowered to $6 from $10 at H.C. Wainwright
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100